论文部分内容阅读
8月13日发表在《Blood》的相关研究称,研究者用3种不同的治疗顺序评估了依鲁替尼联合奥法木单抗疗法的安全性和有效性。研究纳入了慢性粒细胞白血病(CLL)患者/小淋巴细胞淋巴瘤(SLL)幼淋巴细胞白血病或里克特转化的患者,这些患者先前经≥2次治疗失败。本研究中最常见不良反应包括腹泻(70%),输注相关反应(45%)和外周感觉神经病变(44%)。CLL/SLL患者(n=66)中总缓解率分别为100%,79%和71%。4名患者是在接受依鲁替尼治疗之前就发生疾病进展。
Relevant research published in Blood on August 13 said that researchers evaluated the safety and efficacy of ibrutinib in combination with of the two drugs in three different treatment sequences. The study included patients with chronic myelogenous leukemia (CLL) / small lymphocytic lymphoma (SLL) lymphocytic leukemia or rickett converted who had previously failed treatment ≥2 times. The most common adverse reactions included in this study were diarrhea (70%), infusion-related reactions (45%), and peripheral sensory neuropathy (44%). The overall response rates in CLL / SLL patients (n = 66) were 100%, 79%, and 71%, respectively. Four patients developed disease before receiving ibrutinib.